Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schulz, Karen
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	2	102	Europe, US, RoW	ZN-c3, azenosertib	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	04/25	10/25
PREDICT, NCT03448926: The Registry:	Recruiting	N/A	3000	US	Treatment Recommendation Surveys, 7-gene biosignature	PreludeDx, University of South Florida	DCIS	12/25	12/35
Gurka, Marie
PREDICT, NCT03448926: The Registry:	Recruiting	N/A	3000	US	Treatment Recommendation Surveys, 7-gene biosignature	PreludeDx, University of South Florida	DCIS	12/25	12/35